The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Karateev A.E.

Nasonova Research Institute of Rheumatology, Moscow, Russia

Nasonov E.L.

"Research Institute of rheumatology n. a. V. A. Nasonova"

Meloxicam in Russia: 20 years together

Authors:

Karateev A.E., Nasonov E.L.

More about the authors

Journal: Therapeutic Archive. 2016;88(12): 149‑158

DOI: 10.17116/terarkh20168812149-158

Read: 2739 times

Download PDF (RU)
Contact the author
Table of contents

MELOXICAM IN RUSSIA: 20 YEARS TOGETHER
MELOXICAM IN RUSSIA: 20 YEARS TOGETHER

To cite this article:

Karateev AE, Nasonov EL. Meloxicam in Russia: 20 years together. Therapeutic Archive. 2016;88(12):149‑158. (In Russ.)
https://doi.org/10.17116/terarkh20168812149-158

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Effi­cacy and safety of meta­mizole sodium for pain syndrome in adults and children: a systematic review. Russian Journal of Pain. 2024;(4):65-80
Effi­cacy and safety of topi­cal anti­biotic therapy in patients with acute exte­rnal bacterial otitis: resu­lts of a retrospective study. Russian Bulletin of Otorhinolaryngology. 2024;(6):24-27
Open obse­rvational study with a retrospective analysis of the effi­cacy and tole­rability of aceclofenac in patients with acute non-specific low back pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):99-105
On the issue of choosing anesthesia methods: a comparison of gene­ral medi­cine and clinical dentistry. Stomatology. 2025;(1):76-80
Comparing the effi­cacy of divo­zilimab and second-line treatments for rela­psing-remitting multiple scle­rosis in the Russian Fede­ration: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68
Effi­cacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):69-79
Use of a fixed combination of diclofenac and orphenadrine (Neodolpasse) for postoperative analgesia after exte­nded gastrectomy with rese­ction of the lower third of the esophagus. P.A. Herzen Journal of Onco­logy. 2025;(2):52-56
Expe­rience of using ribo­ciclib in the therapy of meta­static breast cancer in a regional onco­logical dispensary. P.A. Herzen Journal of Onco­logy. 2025;(3):89-93
Resu­lts of the inte­rnational multicenter randomized, double-blind, placebo-controlled clinical trial for the evaluation of the effi­cacy and safety of the sequential therapy with ethy­lmethylhydroxypyridine succinate in patients in the acute and early reco­very periods of ischemic stroke (MIR). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):40-53
Costs of home-based respiratory support and oxygen therapy. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):93-102
Abstract:

Meloxicam is one of the most commonly used representatives of the group of nonsteroidal anti-inflammatory drugs prescribed in our country. It has been used in Russian clinical practice for 20 years and established itself as an effective and rather safe analgesic and anti-inflammatory medications. During this period almost 48 million packages of brand-name meloxicam have been sold; millions of people in our country have been successfully treated with this drug. During this period, there have been at least 29 Russian clinical trials of brand-name meloxicam, which covered 3,736 patients. In all the trials, meloxicam has demonstrated a good therapeutic potential (a substantial improvement in more than 75% of patients) and a low incidence of side effects, which averaged 6.4% (30.5% in the control groups). The good tolerability of brand-name meloxicam (Movalis) is confirmed by a total of 120 spontaneous reports of the adverse events due to this drug, which were sent to the Federal Service for Health Supervision in December 2008 to July 2015 (over the last 7 years). This number seems negligible (nearly 30 million packages) if the amount of meloxicam sold over the period is taken into account. Extensive experience in clinical practice with this drug and a wide series of national clinical trials support the good reputation of brand-name meloxicam among Russian physicians and patients. This review briefly gives the data of Russian and main foreign clinical trials of the therapeutic effect and safety of meloxicam.

Keywords:

nonsteroidal anti-inflammatory drugs
meloxicam
efficacy
safety

Authors:

Karateev A.E.

Nasonova Research Institute of Rheumatology, Moscow, Russia

Nasonov E.L.

"Research Institute of rheumatology n. a. V. A. Nasonova"

Close metadata

References:

  1. Nasonova V. Meloxicam (Movalis) is a selective COX-2 inhibitor in clinical practice. Nauchno-prakticheskaya revmatologiya. 2000;4:16-21. (In Russ).
  2. Nasonov E, Tcvetkova E. Selective cyclooxygenase-2 inhibitors: prospects for treating human diseases. Ter Archive. 1998;5:8-14. (In Russ).
  3. Briggs AM, Cross MJ, Hoy DG et al. Musculoskeletal Health Conditions Represent a Global Threat to Healthy Aging: A Report for the 2015 World Health Organization World Report on Ageing and Health. Gerontologist. 2016;56(Suppl 2):S243-255. doi:10.1093/geront/gnw002
  4. Clauw DJ. Diagnosing and treating chronic musculoskeletal pain based on the underlying mechanism(s). Best Pract Res Clin Rheumatol. 2015;29(1):6-19. doi:10.1016/j.berh.2015.04.024
  5. General principles of treatment of musculoskeletal pain. Interdisciplinary consensus. Medical advice. 2015;7, special issue. (In Russ).
  6. Vos T, Barber M, Bell B et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990—2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800. doi:10.1016/S0140-6736(15)60692-4
  7. Juniper M, Le T, Mladsi D. The epidemiology, economic burden, and pharmacological treatment of chronic low back pain in France, Germany, Italy, Spain and the UK: a literature-based review. Expert Opin Pharmacother. 2009;10(16):2581-9252. doi:10.1517/14656560903304063
  8. Litwic A, Edwards M, Dennison E, Cooper C. Epidemiology and burden of osteoarthritis. Br Med Bull. 2013;105:185-199. doi:10.1093/bmb/lds038
  9. Chang DS, Raghavan R, Christiansen S, Cohen SP. Emerging targets in treating pain. Curr Opin Anaesthesiol. 2015;28(4):379-397. doi:10.1097/ACO.0000000000000216
  10. Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. Am Fam Physician. 2013;87 (11):766-772.
  11. Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti-inflammatory drugs. J Pain Res. 2015;8:105-118. doi:10.2147/JPR.S75160
  12. Rainsford K. Anti-inflammatory drugs in the 21st century. Subcell Biochem. 2007;42:3-27. doi:10.1007/1-4020-5688-5_1
  13. Karateev A, Uspensky Y, Pakhomova I, Nasonov E. Brief history of NSAIDs. Nauchno-prakticheskaya revmatologiya. 2012;3:101-111. (In Russ).
  14. Goldstein JL, Cryer B. Gastrointestinal injury associated with NSAID use:a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf. 2015;7:31-41. doi:10.2147/DHPS.S71976
  15. Karateev A, Nasonov E, Yakhno N. Clinical practice guidelines on «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice». Sovremennaya Revmatologiya. 2015;1:4-24. (In Russ).
  16. Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 2013;16(5):821-847. doi:10.18433/J3VW2F
  17. Patrignani P, Patrono C. Cyclooxygenase inhibitors: From pharmacology to clinical read-outs. Biochim Biophys Acta. 2015;1851(4):422-432. doi:10.1016/j.bbalip.2014.09.016
  18. Furst DE. Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 1997;26(6 Suppl 1):21-27. doi:10.1007/978-94-011-4872-6_14
  19. Gates BJ, Nguyen TT, Setter SM, Davies NM. Meloxicam:a reappraisal of pharmacokinetics, efficacy and safety. Exp Op Pharmac. 2005;6(12):2117-2140. doi:10.1517/14656566.6.12.2117
  20. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol Suppl. 1996;102:9-21. doi:10.1007/978-94-011-4872-6_1
  21. Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam:a global analysis of clinical trials. Br J Rheumatol. 1996;35(Suppl 1):68-77. doi:10.1093/rheumatology/35.suppl_1.68
  22. Hawkey C, Kahan A, Steinbruck K et al. Gastrointestinal tolerability of meloxicam com-pared diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxi-cam Large-scale International Study Safety Assessment. Br J Rheumat. 1998;37:1142-1147. doi:10.1093/rheumatology/37.9.937
  23. Dequerker J, Hawkey C, Kahan A et al. Improvement in gastrointestinal tolerability of selective cyclooxyenase (COX)-2 inhibitor, meloxicam, compared with piroxicam:results of the Safety and Efficacy Large Scale Evaluation of COX inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol. 1998;37:946-951. doi:10.1093/rheumatology/37.9.946
  24. Degner F, Sigmund R, Zeidler H. Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clin Ther. 2000;22(4):400-410. doi:10.1016/s0149-2918(00)89009-8
  25. Zeidler H, Kaltwasser J, Leonard J et al. Prescription and tolerability of meloxicam in day-to-day practice. Postmarketing observational cohort study of 13.307 patients in Germany. J Clin Rheumatol. 2002;8:305-315. doi:10.1097/00124743-200212000-00005
  26. Layton D, Heeley E, Hughes K, Shakir SA. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data. Rheumatology (Oxford). 2003;42 (5):622-631. doi:10.1093/rheumatology/keg141
  27. Schoenfeld P. Gastrointestinal safety profile of meloxicam:a meta-analysis and systematic review of randomized controlled trials. Am J Med. 1999;107:48-54. doi:10.1016/s0002-9343(99)00367-8
  28. Yocum D, Fleischmann R, Dalgin P et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis. Arch Intern Med. 2000;160:2947-2954. doi:10.1001/archinte.160.19.2947
  29. Furst D, Kolba K, Fleischmann R et al. Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis:a 12 week multicenter, double blind, dose response study versus placebo and diclofenac. J Rheumatol. 2002;29(3):436-446.
  30. Dougados M, Gueguen A, Nakache J et al. Ankylosing spondylitis:what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford). 1999;38(3):235-244. doi:10.1093/rheumatology/38.3.235
  31. Dreiser R, Le Parc J, Vélicitat P, Lleu P. Oral meloxicam is effective in acute sciatica:two randomised, double-blind trials versus placebo or diclofenac. Inflamm Res. 2001;50(Suppl 1):17-23. doi:10.1007/PL00022375
  32. Akarsu T, Karaman S, Akercan F et al. Preemptive meloxicam for postoperative pain relief after abdominal hysterectomy. Clin Exp Obstet Gynecol. 2004;31(2):133-136.
  33. Weber EW, Slappendel R, Durieux ME et al. COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam. Eur J Anaesthesiol. 2003;20(12):963-966. doi:10.1097/00003643-200312000-00005
  34. Asghar W, Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks:a systematic review. Inflammopharmacology. 2015;23(1):1-16. doi:10.1007/s10787-014-0225-9
  35. www.boehringer-ingelheim.ru
  36. Tsvetkova ES. Movalis in osteoarthritis (data from the Russian study). Ter. Archive. 1999;71(11):48-50. (In Russ).
  37. Tsvetkova E. Assessment of efficacy of a new scheme of Мovalis administration in osteoarthritis and rheumatoidarthritis (data of Russian multicentr study). Nauchno-prakticheskaya revmatologiya. 2005;2:29-32. (In Russ). doi:10.14412/1995-4484-2005-1521
  38. Tsvetkova E, Ionichenok N, Carosino P et al. Clinical and instrumental evaluation of the effect of pharmacotherapy on the course of osteoarthritis of the knee joints. Nauchno-prakticheskaya revmatologiya. 2007;1:69-74. (In Russ).
  39. Kogan K, Zolotareva G, Schmidt E. experience with the use of Movalis in patients with osteoarthritis in clinics of Moscow. Ter. Archive. 1999;11(71):52-54. (In Russ).
  40. Yakushin S, Filonenko S, Kosov I, Sorokina O. Evaluation of the efficacy and tolerability of Movalis in patients with osteoarthrosis. Clin Med. 1999;6(77):47-49. (In Russ).
  41. Lytkina A, Tsurko V, Vorobyev P. Effect of a short course of treatment with Movalis on quality of life of patients with osteoarthritis. Sovremennaya revmatologiya. 2008;2:67-68. (In Russ). doi:10.14412/1996-7012-2008-474
  42. Zamyatina E, Bagirova G. Application of meloxicam (Movalis) and aceclofenac (airtal) in the elderly with osteoarthritis. Izvestija visshikh uchebnikh zavedenij. Povolzshskij region. 2012;1(21):40-46. (In Russ).
  43. Schmidt E, Belozerov I, Bilinska M, Dmitrieva M. Clinical study:parenteral 6-day use of meloxicam in patients with rheumatoid arthritis. Consilium medicum. 2005;8(7):650-653. (In Russ).
  44. Antipova O, Zlobina T, Tupitsina G, Yanysheva A. Movalis in the treatment of seronegative spondyloarthritis according Irkutsk rheumatologic center. Sibirskij Med J. 2001;2(25):65-67. (In Russ).
  45. Mazurov V, Belyaeva I, Anoshenko I. Experience of the use of meloxicam in patients with ankylosing spondylitis. Clin Med. 2001;5:53-55. (In Russ).
  46. Shostak N, Aksenov A, Shemetov D, Arinina E. Experience in the use of Movalis in the syndrome of pain in the lower back (LBP). Ter. Archive. 1999;11(71):50-52. (In Russ).
  47. Shostak N, Shemetov D. Efficacy and tolerability of meloxicam (Movalis) in the syndrome of pain in the lower back compared to diclofenac. Nauchno-prakticheskaya revmatologiya. 2001;1:63-67. (In Russ). doi:10.14412/1995-4484-2001-479
  48. Odinak M, Emelin A. Use of Movalis in the treatment of dorsopathies. J Neurol Psih. 2004;104(12):29-32. (In Russ).
  49. Alekseeva L, Kashevarova N, Toroptsova N, Nikitinskaya O. Assessment of the effectiveness of the "step" therapy Movalis in patients with pain syndrome in the lower back, combined with osteoarthritis and osteoporosis. Nauchno-prakticheskaya revmatologiya. 2005;6:53-56. (In Russ).
  50. Filatova E, Istomina O, Kondrikov A. Efficacy of Movalis in the treatment of acute pain in the lower back. J Neurol Psih. 2005;7:33-37. (In Russ).
  51. Gerasimova O, Parfenov V. Clinical experience with meloxicam (Movalis) in nonspecific back pain and radiculopathy. Neurologyja, neuropsychiatryja, psychosomatika. 2012;2:68-72. (In Russ). doi:10.14412/2074-2711-2012-387
  52. Alexeev V. Meloxicam (Movalis) in neurology:pain in the back. Farmateka. 2012;6:80-84. (In Russ).
  53. Guzeva V, Gaigalas L, Razumovsky M. Movalis in the treatment of dorsopathies. J Neurol Psih. 2004;5:58-59. (In Russ).
  54. Merkoushkina I. Assessment of efficiency of treatment of patients with vertebrogenic radiculopathy. Consilium medicum. 2010;2:101-104. (In Russ).
  55. Akarachkova E, Zaitseva I, Stryapunina N et al. Comprehensive approach to the treatment and prevention of back pain:results of a 6-month study. Med Sovet. 2012;8:72-81. (In Russ).
  56. Shirokov V, Potaturko A, Zakharov Y. Safety and efficacy of Movalis injection in the trigger zone when plumbosolvency syndrome. J Neurol Psih. 2008;9:41-44. (In Russ).
  57. Batysheva T, Kostenko E, Ryl'skiy A, Boyko A. Movalis in the treatment of painful shoulder syndrome in patients with stroke. J Neurol Psih. 2004;12:60-61. (In Russ).
  58. Vlaskin S. Step therapy of Movalis for patients with coccygodynia. Farmateka. 2011;9:71-74. (In Russ).
  59. Zagorodnii N, Zakharyan N, Panteleeva A et al. Use Movalis in operative orthopedics. Farmateka. 2008;16:1-4. (In Russ).
  60. Logvinenko V, Shen N, Kolosov D et al. Choice of NSAIDs as a component of multimodal analgesia in patients with hip arthroplasty. Med Nauka I Obrazovanije Urala. 2012;1:63-66. (In Russ).
  61. Akarachkova E, Zakharova I. Evaluation of the efficacy of Movalis (rectal suppositories) in case of pain syndrome in the pelvis in women in an outpatient gynecological practice. Rossijskij vestnik akushera-ginekologa. 2009;3:78-82. (In Russ).
  62. Lebedev V, Budanov P, Pashkov V. Modern approaches to the treatment of primary dysmenorrhea. Trudnij patcient. 2008;1:30-36. (In Russ).
  63. Tkachenko E. the Use of candles Movalis in outpatient practice urologist. Vrach. 2010;1:65-67. (In Russ).
  64. Zholobova E, Gesheva Z, Konopelko O, Sergeyeva T. The safe use of meloxicam (Movalis) in comparison with some anti-inflammatory drugs in the treatment of juvenile arthritis. Effectivnaja farmakoterapija. 2012;12:42-47. (In Russ).
  65. Borghi B, Aurini L, White PF et al. Long-lasting beneficial effects of periradicular injection of meloxicam for treating chronic low back pain and sciatica. Minerva Anestesiol. 2013;79(4):370-378.
  66. Belyaeva B, Mazurov V, Lvovskaja V. Effectiveness of meloxicam (Movalis) in rheumatic diseases. Farmateka. 2008;5:28-34. (In Russ).
  67. Karateev A. Gastroduodenal complications in patients receiving meloxicam in clinical practice. Nauchno-prakticheskaya revmatologiya. 2006;1:28-33. (In Russ).
  68. Karateev A. Selection criteria non-steroidal anti-inflammatory drugs (NSAIDs) in clinical practice: the view of practitioners. Clinicheskaja farmacologija i terapija. 2015;1:55-60. (In Russ).
  69. Karateev A, Bochkova A, Rumyantseva O, Tugova E, Nasonov E. Use of capsule endoscopy to evaluate the effects of meloxicam anddiclofenac on the small bowel mucosa in patients with ankylosingspondylitis:the first experience. Nauchno-prakticheskaya revmatologiya. 2011;4:31-35. (In Russ). doi:10.14412/1995-4484-2011-58
  70. Balabanova R, Egorova O. Meloxicam is the drug of choice in the treatment of osteoarthritis. Russkij medicinskij zhurnal. 2009;17(7):492-494. (In Russ).
  71. Chichasova N. General medical aspects of the use of meloxicam (Movalis) in clinical practice: efficacy and safety. Sovremennaja revmatologija. 2012;4:76-85. (In Russ). doi:10.14412/1996-7012-2012-769
  72. Alekseev V, Alekseyev A. Clinical efficacy and safety of Movalis in the treatment of pain in the lower back. Consilium Medicum. 2014;16(2):57-62. (In Russ).
  73. Tsvetkova E, Belousov D, Afanas'eva E. Pharmacoeconomic analysis of the use of Movalis in patients with osteoarthrosis and rheumatoid arthritis. Kachestvennaja klinicheskaja praktika. 2015;1:66-76. (In Russ).
  74. Shostak N, Klimenko A. Nonsteroidal anti-inflammatory drugs in modern clinical practice. Effectivnaja farmakoterapija. 2014;17:26-32. (In Russ).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.